Teva Pharmaceutical Industries Limited Announces Global In-Market Fourth Quarter Sales Of Its Blockbuster Copaxone(R) Increased 24% To $323 Million

JERUSALEM--(BUSINESS WIRE)--Jan. 30, 2006--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group’s financial results, that global in-market sales of Copaxone(R) reached $323 million in the fourth quarter ended December 31, 2005, an increase of 24% over the comparable quarter of 2004. For the full year 2005, global in-market sales of Copaxone(R) reached an all-time high of $1,176 million, an increase of 26% over 2004.

MORE ON THIS TOPIC